TY - JOUR
T1 - Molecular characteristics of glioblastoma with 1p/19q co-deletion
AU - Mizoguchi, Masahiro
AU - Yoshimoto, Koji
AU - Ma, Xinlong
AU - Guan, Yanlei
AU - Hata, Nobuhiro
AU - Amano, Toshiyuki
AU - Nakamizo, Akira
AU - Suzuki, Satoshi
AU - Iwaki, Toru
AU - Sasaki, Tomio
N1 - Funding Information:
Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan; grant number: 2390280 (M. Mizoguchi).
PY - 2012/7
Y1 - 2012/7
N2 - Recent developments in molecular analysis have revealed genetic alterations in human gliomas. Loss of heterozygosity (LOH) is a critical molecular marker for classification of human glioma, and is useful for predicting outcome. Our previous LOH study identified a small subgroup of glioblastoma (GBM), with 1p/19q co-deletion, with a favorable clinical outcome. In this study, we investigated molecular pathological features of eight GBM with 1p/19q co-deletion compared with "classic" GBM and anaplastic oligodendroglioma (AO). We estimated EGFR gene amplification, EGFRvIII expression, CDKN2A (p16) homozygous deletion, and isocitrate dehydrogenase 1/2 (IDH1/2) gene mutations. We also conducted an analysis of the expression of proneural genes (DLL3, OLIG2, SOX2). On histopathological review, only one GBM was diagnosed as glioblastoma with oligodendroglioma component (GBMO). Loss of chromosomes 10 and 17p is common, and neither IDH1/2 mutations nor EG-FRvIII expression were detected in GBM with 1p/19q codeletion. The expression profile revealed high expression of the OLIG2 gene in this subgroup. High expression of proneural gene OLIG2 without EGFRvIII expression may be associated with a favorable clinical outcome; however, IDH1/2 gene status and the extent of LOH regions may indicate that this small subgroup of GBM is a distinct genetic subgroup from oligodendroglial tumors.
AB - Recent developments in molecular analysis have revealed genetic alterations in human gliomas. Loss of heterozygosity (LOH) is a critical molecular marker for classification of human glioma, and is useful for predicting outcome. Our previous LOH study identified a small subgroup of glioblastoma (GBM), with 1p/19q co-deletion, with a favorable clinical outcome. In this study, we investigated molecular pathological features of eight GBM with 1p/19q co-deletion compared with "classic" GBM and anaplastic oligodendroglioma (AO). We estimated EGFR gene amplification, EGFRvIII expression, CDKN2A (p16) homozygous deletion, and isocitrate dehydrogenase 1/2 (IDH1/2) gene mutations. We also conducted an analysis of the expression of proneural genes (DLL3, OLIG2, SOX2). On histopathological review, only one GBM was diagnosed as glioblastoma with oligodendroglioma component (GBMO). Loss of chromosomes 10 and 17p is common, and neither IDH1/2 mutations nor EG-FRvIII expression were detected in GBM with 1p/19q codeletion. The expression profile revealed high expression of the OLIG2 gene in this subgroup. High expression of proneural gene OLIG2 without EGFRvIII expression may be associated with a favorable clinical outcome; however, IDH1/2 gene status and the extent of LOH regions may indicate that this small subgroup of GBM is a distinct genetic subgroup from oligodendroglial tumors.
UR - http://www.scopus.com/inward/record.url?scp=84865237264&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84865237264&partnerID=8YFLogxK
U2 - 10.1007/s10014-012-0107-z
DO - 10.1007/s10014-012-0107-z
M3 - Article
C2 - 22736234
AN - SCOPUS:84865237264
SN - 1433-7398
VL - 29
SP - 148
EP - 153
JO - Brain Tumor Pathology
JF - Brain Tumor Pathology
IS - 3
ER -
